Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 30
---
 and Series L Warrants will have no rights with respect to the Depositary Shares underlying such Pre-Funded Warrants and Series
L Warrants. Upon exercise of the Pre-Funded Warrants and Series L Warrants, as applicable, the holders will be entitled to exercise the
rights of an Depositary Share holder only as to matters for which the record date occurs after the exercise date.

The Pre-Funded Warrants and Series L Warrants are speculative in nature.

The Pre-Funded Warrants and
Series B Warrants do not confer any rights of Depositary Share ownership on their respective holders, such as voting rights or the right
to receive dividends, but rather merely represent the right to acquire Depositary Shares at a fixed price.

The Series L Warrants may not have value.

The Series L Warrants being offered by us
in this offering will have an initial exercise price of 225% of the public offering price of each Unit in this offering, and expire on
the two and a half--year anniversary of the initial exercise date. In the event that our Depositary Shares do not exceed the exercise
price of the Series L Warrants during the period when such warrants are exercisable, such warrants may not have any value.

The terms of the warrants could impede our ability to enter into certain transactions or obtain additional financing.

The terms of the warrants
require us, upon the consummation of any “fundamental transaction” (as defined in the securities), to, among other obligations,
cause any successor entity resulting from the fundamental transaction to assume all of our obligations under the warrants and the associated
transaction documents. In addition, holders of warrants are entitled to participate in any fundamental transaction on an as-converted
or as-exercised basis, which could result in the holders of our Depositary Shares receiving a lesser portion of the consideration from
a fundamental transaction. The terms of the warrants could also impede our ability to enter into certain transactions or obtain additional
financing in the future.

We may be required to repurchase our Series L Warrants.

Under the terms of the Series
L Warrants, in the event of certain “Fundamental Transactions” (as defined in the related warrant agreement, which generally
includes any merger with another entity, the sale, transfer or other disposition of all or substantially all of our assets to another
entity, or the acquisition by a person of more than 50% of our Ordinary Shares), each warrant holder will have the right at any time prior
to the